Read Summary

The FDA’s ODAC voted unanimously that there was a lack of evidence to support approval of l-omburtamab for a rare pediatric cancer. The FDA has a November 30 deadline to decide if it will approve the drug.
Medscape Medical News

Print Friendly, PDF & Email